NeuroTalk Support Groups

NeuroTalk Support Groups (https://www.neurotalk.org/)

- Reflex Sympathetic Dystrophy (RSD and CRPS) (https://www.neurotalk.org/reflex-sympathetic-dystrophy-rsd-and-crps-/)

- - Nucynta (https://www.neurotalk.org/reflex-sympathetic-dystrophy-rsd-and-crps-/90850-nucynta.html)

I got a prescription for a new pain med from my PM Doctor today - NUCYNTA.

No pharmacies in my area have it, but one ordered it and will be here Friday.

My Doctor stated that it was a new pain med (CII).

I thought this may be something someone may be interested in or maybe trying.

what is it similar to?

Here is some info on it:

http://en.wikipedia.org/wiki/Tapentadol

Quote:

Originally Posted by mrsD (Post 528211)

Here is some info on it:

http://en.wikipedia.org/wiki/Tapentadol

That was an unusually interesting Wikipedia article. It's wild to see a manufacturer so out in front to say "please don't make it a schedule III drug because we can't compete with the generic opiods." Remarkably like watching a movie producer argue in favor of a less restrictive rating. Except of course that the manufacturer can't opt for "this drug is unscheduled."

Mike

Quote:

Originally Posted by fmichael (Post 528336)

Yes, Mike, the drug industry is amazing sometimes.

I think this drug approval is reflecting the "new" FDA.
You know Ultram, is similar to this new drug. It has norepi and mu activity but is less potent(it is also from McNeil). It has a subset of people who become dependent on it. Forge RXs for it even. I've been trying Ultram for my pain issues recently, and it really knocked me down with a euphoria/tripping I have never had before. I was hoping to using it at night sometimes but it is not turning out to be helpful ..the pain dose is the side effect dose for me. 1/2 tab doesn't do much but does reduce the "tripping". (I had Demerol when I had surgery 28 yrs ago, and never had THAT). So I guess the FDA wishes it had put Ultram on controlled status too.

There are changes coming in the treatment of chronic pain.
I think this new drug approval reflects that.